Introduction –
Dr Abha Kumari is a radiation oncologist, working in HCG EKO Cancer Centre, Kolkata as a Consultant. She has completed her MBBS from RIMS (Ranchi Institute of Medical Sciences, Ranchi) and DNB (Diplomate of National Board) Radiation Oncology From Amrita Institute of Medical Sciences, Kochi. She has more than 12 years experience in Radiation oncology, working in Premier institutes of India. She has been trained in IMRT, IGRT, SRS, SRT. She has extensive experience in research field. She was actively involved in training of radiation oncologist for DNB radiotherapy at Mahavir Cancer Center, Patna. She has special interest in Head and Neck cancer, brain cancer and breast cancer
Education –
- Graduate from Ranchi Institute of Medical Sciences
- Post Graduate (DNB) from Amrita Institute of Medical Sciences, Cochin, Kerala.
Working experience in field of Oncology -
- Worked as Resident in Radiation Oncology department in Fortis Noida from March 2010 to July 2010.
- Worked as registrar in Tata Medical Center, Kolkata from Feb 2012 to May 2014.
- Worked as Senior resident in Paras HMRI, Patna from July 2014 to Oct 2015
- Worked as Junior Consultant, Mahavir Cancer Sansthan Patna from Nov 2015 to July 2017
- Worked as Clinical associate in Tata Medical Center, Kolkata from Oct 2017 to Oct 2021.
Research Experience –
- Co investigator in National cancer registry program (NCRP) in Mahavir Cancer Sansthan, Patna
- Co-Ordinator in Onco-collect project of Ramesh Nimmagadda Cancer Foundation in Mahavir Cancer Sansthan,Patna
- Co- Investigator in a phase III, multicentre, randomized, double-blind, placebo-controlled study of Atezolizumab (Anti-PDL1 Antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
- CO-investigator in a Phase II, multicentre, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor ( HR ) positive, HER2 – negative advanced breast cancer ( aBC ), who have progressed on or after CDK 4/6 inhibitor treatment in metastatic breast cancer.
- Co-investigator in a prospective, multicentre, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN)
- Co-investigator in a Prospective, multicentre, randomized, double blind Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer
- Co-investigator in a long-term Follow up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC.
- Co-investigator in a Randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer.
- Co-investigator in a Phase III, Double Blind, Placebo-Controlled, Randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel As a treatment for patients with Locally Advanced Unresectable or Metastatic Triple – Negative Breast Cancer.
- Co-investigator in a HYPOfractionated Radiation Therapy comparing a standard radiotherapy schedule (over three weeks) with a novel one week schedule in Adjuvant breast cancer: An open label randomised controlled study (HYPORT- Adjuvant)
- Co-investigator in a HYPO-Fractionated Radiotherapy schedule of 26 Gy in 5 fractions with simultaneous integrated boost (6 Gy) in advanced incurable breast cancer : A prospective phase I/II study.
- Co-investigator in a Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer.
- Co-investigator in a phase III, double-blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumors.
- Co-investigator in a Intensifying radiation treatment in advanced/ poor prognosis laryngeal, hypopharyngeal (LH) and oropharyngeal cancers (OPC) using PET –CT based dose escalation strategies.
Publication –
1. Rita R, Singh U, Trivedi V, Chauhan R, Kumari A (2017) Determinants of Survival of Cervical Cancer: A Hospital Based Study. Gynecol Obstet 7: 437. doi:10.4172/2161-0932.1000437.
2. HYPOfractionated Radiation Therapy comparing a standard radiotherapy schedule (over three weeks) with a novel one week schedule in Adjuvant breast cancer: An open-label randomised controlled study (HYPORT-Adjuvant): study protocol for a multicenter, randomized phase III trial. S Chatterjee, H Adjuvant - Authorea Preprints, 2020.
3. Chatterjee S, Chakraborty S; HYPORT Adjuvant Author Group. Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized phase III trial. Trials. 2020;21(1):819. Published 2020 Sep 30. doi:10.1186/s13063-020-04751-y
